Study of CS060380 tablets for NASH (fatty liver disease)
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests an experimental pill called CS060380 for people with NASH (a type of fatty liver disease that can cause liver damage). You may qualify if you have a liver biopsy showing NASH with early-to-moderate scarring, or an MRI showing at least 10% liver fat, and your liver enzymes are stable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a liver biopsy showing NASH with at least some fibrosis (stage F1-F3) OR an MRI that shows your liver is at least 10% fat.
- You have had stable liver enzyme levels (ALT/AST) in recent tests, and your ALT or AST is not too high (less than 5 times the normal upper limit).
- You have not had significant weight change (5% in 3 months or 10% in 6 months) and you do not have a history of heavy drinking in the past year.
- You are willing to use effective birth control (if you or your partner could become pregnant) and avoid strenuous exercise before blood draws.
- You do not have other serious liver diseases, heart problems (like recent heart attack or uncontrolled heart failure), or uncontrolled diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the heart medication digoxin can help people with NASH (fatty liver disease with inflammation), who have moderate liver scarring. You will receive digoxin or a placebo for 24 weeks and have a liver biopsy before and after treatment to see if the medication reduces liver damage.
This study tests an experimental drug called SNP-610 for a liver condition called NASH (fatty liver with inflammation). The goal is to see if the drug helps improve liver health compared to a placebo.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
This study tests a new injected drug (TQA2225/AP025) that may help reduce liver fat and inflammation in people with NASH (a type of fatty liver disease with scarring). It’s for adults who have had a recent liver biopsy and MRI confirming NASH and moderate liver fat.
This trial tests a new drug called HP515 for people with non-alcoholic fatty liver disease, including NASH or MASH. It aims to see if the drug can help reduce liver fat and improve liver health.
This trial tests ADI-PEG 20 against a placebo (inactive pill) to see if it improves liver disease in people with NASH and compensated cirrhosis. It may help by targeting liver fat and inflammation seen on scans and biopsy.
Hear when a new NASH trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.